Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 379
Filtrar
1.
Biodegradation ; 34(3): 253-262, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36797384

RESUMEN

In the present study, the potential inhibitory effect of biologically pre-treated vegetable tannery wastewater (TW) on anammox granular biomass was evaluated. Beside high organic and chemicals load, vegetable TW are characterised by high salinity and high tannins concentration, the latter belonging to a group of bio-refractory organic compounds, potentially inhibitory for several bacterial species. Recalcitrant tannin-related organic matters and salinity were selected as the two potential inhibitory factors and studied either for their separate and combined effect. Parallel batch tests were performed, with biomass acclimated and non-acclimated to salinity, testing three different conditions: non-saline control test with non-acclimated biomass (CT); saline control test with acclimated biomass (SCT); vegetable tannery wastewater test with acclimated biomass (TWT). Compared with non-saline CT, the specific anammox activity in tests SCT and TWT showed a reduction of 28 and 14%, respectively, suggesting that salinity, at conductivity values of 10 mS/cm (at 25 °C), was the main impacting parameter. As a general conclusion, the study reveals that there is no technical limitation for the application of the anammox process to vegetable TW, but preliminary biomass acclimation as well as regular biomass activity monitoring is recommended in case of long-term applications. To the best of our knowledge, this is the first work assessing the impact of vegetable TW on anammox biomass.


Asunto(s)
Compuestos de Amonio , Aguas Residuales , Verduras , Reactores Biológicos/microbiología , Nitrógeno , Biomasa , Desnitrificación , Oxidación Anaeróbica del Amoníaco , Oxidación-Reducción , Anaerobiosis
2.
J Eur Acad Dermatol Venereol ; 35(11): 2118-2120, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34647666
7.
Artículo en Inglés | MEDLINE | ID: mdl-32746604

RESUMEN

This article has been retracted at the request of the Editor. After a thorough investigation the Editor-in-Chief has retracted this article as it showed evidence of substantial manipulation of the peer review.

8.
Artículo en Inglés | MEDLINE | ID: mdl-32668870

RESUMEN

Ahead of Print article withdrawn by publisher.

12.
J Biol Regul Homeost Agents ; 33(3): 817-819, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31184104

RESUMEN

Pattern hair loss (i.e., androgenetic alopecia) is a common condition afflicting approximately fifty percent of men and women by the age of fifty. Currently, topical minoxidil is the only US FDA approved drug for the treatment of pattern hair loss in men and women.


Asunto(s)
Alopecia/tratamiento farmacológico , Minoxidil/farmacología , Sulfotransferasas/metabolismo , Femenino , Humanos , Masculino
14.
Dermatol Ther ; 31(6): e12741, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30226287

RESUMEN

Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA). Minoxidil is a pro-drug converted into its active form, minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles. Previously, we demonstrated that sulfotransferase activity in hair follicles predicts response to topical minoxidil in the treatment of AGA. In the human liver, sulfotransferase activity is significantly inhibited by salicylic acid. Low-dose OTC aspirin (75-81 mg), a derivative of salicylic acid, is used by millions of people daily for the prevention of coronary heart disease and cancer. It is not known whether oral aspirin inhibits sulfotransferase activity in hair follicles, potentially affecting minoxidil response in AGA patients. In the present study, we determined the follicular sulfotransferase enzymatic activity following 14 days of oral aspirin administration. In our cohort of 24 subjects, 50% were initially predicted to be responders to minoxidil. However, following 14 days of aspirin administration, only 27% of the subjects were predicted to respond to topical minoxidil. To the best of our knowledge, this is the first study to report the effect of low-dose daily aspirin use on the efficacy of topical minoxidil.


Asunto(s)
Alopecia/tratamiento farmacológico , Aspirina/administración & dosificación , Inhibidores Enzimáticos/administración & dosificación , Folículo Piloso/efectos de los fármacos , Minoxidil/administración & dosificación , Profármacos/administración & dosificación , Sulfotransferasas/antagonistas & inhibidores , Administración Cutánea , Adulto , Alopecia/diagnóstico , Alopecia/fisiopatología , Aspirina/efectos adversos , Interacciones Farmacológicas , Inhibidores Enzimáticos/efectos adversos , Folículo Piloso/enzimología , Folículo Piloso/crecimiento & desarrollo , Humanos , Masculino , Minoxidil/análogos & derivados , Minoxidil/metabolismo , Profármacos/metabolismo , Medición de Riesgo , Sulfotransferasas/metabolismo , Resultado del Tratamiento , Adulto Joven
15.
J Biol Regul Homeost Agents ; 32(4): 937-940, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30043580

RESUMEN

Minoxidil is the only US FDA-approved topical drug for the treatment of female and male pattern hair loss. Previously, it was demonstrated that topical minoxidil is metabolized to its active metabolite, minoxidil sulfate, by sulfotransferase enzymes located in the outer root sheath of hair follicles. The expression of sulfotransferase in the scalp varies greatly between individuals, and this difference in expression explains the varied response to minoxidil treatment. Previously, we have demonstrated the clinical utility of detecting sulfotransferase in plucked hair follicles to predict minoxidil response in pattern hair loss patients. Typically, exogenous exposure to substrates affects the expression of the enzymatic system responsible for their metabolism. For example, Phase I metabolizing enzymes, such as the cytochrome P450 family of enzymes, are known to be up-regulated in the presence of xenobiotic substrates. However, it is not known if Phase II metabolizing enzymes, such as the sulfotransferase family of enzymes, are similarly affected by the presence of substrates. In this study, we recruited 120 subjects and analyzed their sulfotransferase enzymatic activity before and after treatment with topical minoxidil. Adjusting the results for biologic (within subject) variability, we discovered that the sulfotransferase enzymatic system expression is stable over the course of minoxidil treatment. To the best of our knowledge, this is the first study to demonstrate the stability of sulfotransferase, a Phase II metabolizing enzyme, over the course of minoxidil treatment.


Asunto(s)
Folículo Piloso/efectos de los fármacos , Folículo Piloso/enzimología , Minoxidil/metabolismo , Minoxidil/uso terapéutico , Sulfotransferasas/metabolismo , Administración Tópica , Adulto , Alopecia/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad
16.
J Biol Regul Homeost Agents ; 31(4): 1013-1016, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29254307

RESUMEN

In recent years, dermatologists have observed an increase in the incidence of male androgenetic alopecia (AGA). In a survey of 41 dermatologists, 88% reported an increase in incidence of AGA in men younger than 30 years. This phenomenon has no apparent explanation. However, due to the strong genetic inheritance component of AGA, a social or environmental factor which favours the inheritance of genes that increase the risk of developing AGA is suspected. To date, the strongest predictor of AGA in men has been the length of the CAG repeat located in the androgen receptor gene (AR gene) on the X chromosome. The same genetic variant in women is associated with ovulation at a later age, higher antral follicle count, and lower risk for premature ovarian failure. This led us to theorize that, due to social pressure to conceive later in life, women carriers of the short CAG repeat in the AR gene would have a selective advantage to conceive later in life and would thus favour male offspring exhibiting AGA.


Asunto(s)
Alopecia/genética , Predisposición Genética a la Enfermedad , Herencia Materna , Receptores Androgénicos/genética , Adulto , Factores de Edad , Alopecia/diagnóstico , Cromosomas Humanos X/química , Cromosomas Humanos X/metabolismo , Femenino , Fertilización/genética , Expresión Génica , Humanos , Masculino , Folículo Ovárico/citología , Folículo Ovárico/fisiología , Ovulación/genética , Receptores Androgénicos/química , Selección Genética , Factores Socioeconómicos , Repeticiones de Trinucleótidos
17.
J Biol Regul Homeost Agents ; 31(4): 1037-1041, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29254311

RESUMEN

Depression and mood disorders often develop after dermatological conditions which could be primary or secondary to dermatological pathology. The oxidative and psychological stress cause physiological changes in the body. Shift in the methylation pathway, elevated cortisol, lowered neurotransmitter levels and lowered immune system allow infection to penetrate the body and lead to anxiety and depression. Here, a case report of a 20 year old male patient is presented to show how infectious skin lesions, unresponsive to the usual treatment plan, were treated after using a multipronged approach of addressing systemic infection of Escherichia coli, elevated cortisol levels and nutritional imbalances.


Asunto(s)
Ansiedad/psicología , Depresión/psicología , Infecciones por Escherichia coli/psicología , Enfermedades Cutáneas Bacterianas/psicología , Estrés Psicológico/psicología , Antibacterianos/uso terapéutico , Ansiedad/complicaciones , Ansiedad/tratamiento farmacológico , Ansiedad/microbiología , Cefoperazona/uso terapéutico , Depresión/complicaciones , Depresión/tratamiento farmacológico , Depresión/microbiología , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Humanos , Hidrocortisona/sangre , Masculino , Fosfatidilserinas/uso terapéutico , Probióticos/uso terapéutico , Enfermedades Cutáneas Bacterianas/complicaciones , Enfermedades Cutáneas Bacterianas/tratamiento farmacológico , Enfermedades Cutáneas Bacterianas/microbiología , Estrés Psicológico/complicaciones , Estrés Psicológico/tratamiento farmacológico , Estrés Psicológico/microbiología , Sulbactam/uso terapéutico , Resultado del Tratamiento , Adulto Joven
18.
J Biol Regul Homeost Agents ; 31(4): 1049-1053, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29254313

RESUMEN

Topical minoxidil is the only topical drug approved by the US Food and Drug Administration (FDA) for the treatment of androgenetic alopecia. However, the exact mechanism by which minoxidil stimulates anagen phase and promotes hair growth is not fully understood. In the late telegen phase of the hair follicle growth cycle, stem cells located in the bulge region differentiate and re-enter anagen phase, a period of growth lasting 2-6 years. In androgenetic alopecia, the anagen phase is shortened and a progressive miniaturization of hair follicles occurs, eventually leading to hair loss. Several studies have demonstrated that minoxidil increases the amount of intracellular Ca2+, which has been shown to up-regulate the enzyme adenosine triphosphate (ATP) synthase. A recent study demonstrated that ATP synthase, independent of its role in ATP synthesis, promotes stem cell differentiation. As such, we propose that minoxidil induced Ca2+ influx can increase stem cell differentiation and may be a key factor in the mechanism by which minoxidil facilitates hair growth. Based on our theory, we provide a roadmap for the development of a new class of drugs for the treatment of androgenetic alopecia.


Asunto(s)
Alopecia/tratamiento farmacológico , Folículo Piloso/efectos de los fármacos , Minoxidil/uso terapéutico , Mitocondrias/efectos de los fármacos , ATPasas de Translocación de Protón Mitocondriales/genética , Células Madre/efectos de los fármacos , Vasodilatadores/uso terapéutico , Adulto , Alopecia/enzimología , Alopecia/genética , Alopecia/patología , Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Expresión Génica , Folículo Piloso/enzimología , Folículo Piloso/patología , Humanos , Transporte Iónico/efectos de los fármacos , Masculino , Persona de Mediana Edad , Mitocondrias/enzimología , ATPasas de Translocación de Protón Mitocondriales/metabolismo , Células Madre/enzimología , Células Madre/patología , Regulación hacia Arriba
19.
J Biol Regul Homeost Agents ; 31(2 Suppl. 2): 35-37, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28702962

RESUMEN

Neotrombicula autumnalis is an arthropod living in the soil and parasitizes animals only in its larval stage. Depending on climatic conditions, one to five life cycles can take place in a single year. Human infestation is probably underestimated and can be easily missed due to non-pathognomonic cutaneous manifestations in absence of systemic signs. We describe a case of human trombiculiasis and discuss the diagnostic and therapeutic management of this 'synanthropic' dermatosis.

20.
J Biol Regul Homeost Agents ; 31(2 Suppl. 2): 1-13, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28702959

RESUMEN

The aim of the present study is to evaluate the effects on skin regeneration of a new collagen matrix (CM-10826) when used in different combination with or without growth factors, using skin regeneration without membrane as control. An area of 10x15 cm on rabbit back was shaved and three circular wounds on test side were covered with a differently soaked membrane. The first wound was soaked with Epidermal Growth Factor (EGF, 26mg/130mL) (Test EGF), the second with Platelet-Derived Growth Factor (PDGF, 6mg/120mL) (Test PDGF) and the third with EGF (13mg/65mL) and PDGF (3mg/60mL) (Test EGF+PDGF). On the control side, there was a dry membrane. After 7 days, the experiment was concluded. Healing process was evaluated at day 2 and 6 postoperatively. Analysis was made clinically and with light microscopy (LM), transmission electron microscopy (TEM) and scanning electron microscopy (SEM). Analyses with LM of Test EGF showed evidence of neoangiogenesis and good epithelium growth. Test PDGF resulted in moderate angiogenesis, less evident epithelial growth and more evident mesenchymal growth than Test EGF. Test EGF+PDGF showed rich angiogenesis, massive growth of epithelium and mesenchymal tissue. Control side showed weak angiogenesis, regenerating wound margin with normal epithelium and less dense mesenchymal layer. Analysis at TEM and SEM confirmed what was noticed at LM. In vivo studies on rabbits have shown that membrane CM10826 is well tolerated, it gives neither inflammation nor foreign body reactions and does not disturb healing process. CM10826 is safe, modulates angiogenesis and induces migration and proliferation of keratinocytes.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...